Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 June 1; Volume 36; 100911.; DOI:10.1016/j.eclinm.2021.100911
Batista C, Shoham S, Ergonul O, Hotez PJ, Bottazzi ME, et al.
E Clinical Medicine. 2021 June 1; Volume 36; 100911.; DOI:10.1016/j.eclinm.2021.100911
Journal Article > ReviewFull Text
E Clinical Medicine. 2023 May 1; Volume 59; 101965.; DOI:10.1016/j.eclinm.2023.101965
Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, et al.
E Clinical Medicine. 2023 May 1; Volume 59; 101965.; DOI:10.1016/j.eclinm.2023.101965
The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients' immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches.
Journal Article > CommentaryFull Text
PLoS Negl Trop Dis. 2013 October 31; Volume 7 (Issue 10); e2300.; DOI:10.1371/journal.pntd.0002300
Hotez PJ, Dumonteil E, Cravioto MB, Bottazzi ME, Tapia-Conyer R, et al.
PLoS Negl Trop Dis. 2013 October 31; Volume 7 (Issue 10); e2300.; DOI:10.1371/journal.pntd.0002300
Journal Article > CommentaryFull Text
Lancet Child Adolesc Health. 2023 November 1; Volume 7 (Issue 11); 751-753.; DOI:10.1016/S2352-4642(23)00214-6
May T, Babirekere-Iriso E, Traoré M, Berbain E, Ahmed M, et al.
Lancet Child Adolesc Health. 2023 November 1; Volume 7 (Issue 11); 751-753.; DOI:10.1016/S2352-4642(23)00214-6
Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 June 1; Volume 36; 100925.; DOI:10.1016/j.eclinm.2021.100925
Naniche D, Hotez PJ, Bottazzi ME, Ergonul O, Figueroa J, et al.
E Clinical Medicine. 2021 June 1; Volume 36; 100925.; DOI:10.1016/j.eclinm.2021.100925
Journal Article > CommentaryFull Text
E Clinical Medicine. 2021 August 3; Volume 39; DOI:10.1016/j.eclinm.2021.101053
Hotez PJ, Batista C, Amor YB, Ergonul O, Figueroa J, et al.
E Clinical Medicine. 2021 August 3; Volume 39; DOI:10.1016/j.eclinm.2021.101053
A Lancet Commission for COVID-19 task force is shaping recommendations to achieve vaccine and therapeutics access, justice, and equity. This includes ensuring safety and effectiveness harmonized through robust systems of global pharmacovigilance and surveillance. Global production requires expanding support for development, manufacture, testing, and distribution of vaccines and therapeutics to low- and middle-income countries (LMICs). Global intellectual property rules must not stand in the way of research, production, technology transfer, or equitable access to essential health tools, and in context of pandemics to achieve increased manufacturing without discouraging innovation. Global governance around product quality requires channelling widely distributed vaccines through WHO prequalification (PQ)/emergency use listing (EUL) mechanisms and greater use of national regulatory authorities. A World Health Assembly (WHA) resolution would facilitate improvements and consistency in quality control and assurances. Global health systems require implementing steps to strengthen national systems for controlling COVID-19 and for influenza vaccinations for adults including pregnant and lactating women. A collaborative research network should strive to establish open access databases for bioinformatic analyses, together with programs directed at human capacity utilization and strengthening. Combating anti-science recognizes the urgency for countermeasures to address a global-wide disinformation movement dominating the internet and infiltrating parliaments and local governments.
Journal Article > CommentaryFull Text
PLOS Med. 2021 September 13; Volume 18 (Issue 9); e1003772.; DOI:10.1371/journal.pmed.1003772
Figueroa J, Hotez PJ, Batista C, Ergonul O, Gilbert S, et al.
PLOS Med. 2021 September 13; Volume 18 (Issue 9); e1003772.; DOI:10.1371/journal.pmed.1003772
Journal Article > CommentaryFull Text
E Clinical Medicine. 2022 January 1; Volume 43; 101230.; DOI:10.1016/j.eclinm.2021.101230
Batista C, Hotez PJ, Ben Amor Y, Kim JH, Kaslow D, et al.
E Clinical Medicine. 2022 January 1; Volume 43; 101230.; DOI:10.1016/j.eclinm.2021.101230